Alimentary Pharmacology & Therapeutics

Article	Citations
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply	195
Issue Information	136
AP&T: Editors' Declarations of Interest	120
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification	117
Issue Information	111
	105
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	86
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	82
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease	79
	77
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	74
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply	69
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	65
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply	64
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease	61
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis	59
Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea	59
Issue Information	59
	57
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	56
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	55
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply	54
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	54
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	53
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	53

Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	51
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	51
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	51
Editorial: Plants against animals	51
Letter: Ozanimod and latent tuberculosis	50
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	49
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	49
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	48
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score	47
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	47
Editorial: Can we predict or not predict response to hypnotherapy? That is the question	45
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply	42
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study	41
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis	40
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	40
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected	40
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials	40
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment	40
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	40
CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy	39
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	39
No value of non‐selective beta‐blockers after TIPS‐insertion	39
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply	38
Editorial: The future of managing drug induced liver injury	38
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients	37
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase I	37
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes	36
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	36
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases	36
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies	36
Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration	35
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy	35
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation	35
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o	35
Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease	34
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment	34
Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis	34
Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance	34
Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis	34
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply	34
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	34
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study	34
Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply	33
Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis	33
Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease	33
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	33
	32
Issue Information	32
Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply	32
	32

Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US	32
	32
Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply	31
Letter: The importance of histological assessment—a further stride inSTRIDE. Authors' reply	31
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply	31
Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply	31
Editorial: Feeling better about NASH—Authors' reply	31
Letter: chronic HDV infection—is ignorance bliss? Authors' reply	31
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism	31
Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?	31
Editorial: changes of health‐related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD—authorsʼ reply	31
Editorial: reducing false alarms with oesophagogastric junction outflow obstruction	31
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply	30
Faecal incontinence: Retentive, non‐retentive and when to suspect organic pathology	30
Letter: Irritable bowel syndrome and antibiotics—Authors' reply	30
Letter: diet‐responsive or just diet‐adherent in eosinophilic oesophagitis. Where is the dietitian?	30
Letter: hereditary role in non‐alcoholic fatty liver disease	30
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study	29
Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease	28
Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma	28
	28
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease—Authors' reply	28
Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply	28
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome	28
Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients	28
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection	28
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure	27
Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis	27
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients	27
Issue Information	27
Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences	27
Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Repl	26
	26
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease	26
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series	26
Editorial: food insecurity, diet quality, racial and ethnic disparities in non‐alcoholic fatty liver disease	26
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras	26
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality	26
Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis	25
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply	25
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'	25
Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System	25
Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologi	25
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy	25
Letter: Albumin—Does formulation matter?	25
Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply	25
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound	24
Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial	24
Trends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study	24
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance	24
Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor	24
Systematic review: The use of large language models as medical chatbots in digestive diseases	24
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas	24
Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study	24
One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study	24
Autoimmune hepatitis and metabolic syndrome‐associated disease development: a U.S. cohort study	24
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC	23
Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply	23
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT	23
Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With	23
	23
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States	23
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs	23
Trends in aetiology‐based hospitalisation for cirrhosis before and during the COVID‐19 pandemic in the United States	23
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Pa	23
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome	23
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers	22
Editorial: The Role of Liver Biopsy in ANA Positive Subjects	22
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?	22
	22
Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom	22
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis	22
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply	22
	22
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments	22
Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp2	22
Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease	22
	22
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply	21
Early serum ammonia variation in critically ill patients with cirrhosis: A multicentre cohort study	21

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH	21
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still Out	21
	21
Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes	21
Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population‐based study	21
Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study	21
Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?	21
Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns	21
Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach	21
Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C	21
	21
Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’	21
Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure	20
Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C	20
Editorial: PPIs and gastric cancer – Are we dealing with a carcinogen? Authors' reply	20
Letter: Shifting focus—From ChatGPT to specialised medical LLMs	20
Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply	20
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply	20
Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis	20
Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?	20
Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome	20
Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply	19
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease	19
IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease	19
Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the ‘gluten’ from ‘non‐coeliac gluten sensitivity’	19
Letter: efficacy of peppermint oil in irritable bowel syndrome	19
Editorial: potassium‐competitive acid blockers—is there a role for more complete acid suppression?	19
Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV<	19
Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply	19
Letter: Should ulcerative colitis be monitored more or less invasively?	19
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome	19
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply	19
Editorial: improving the use of Montreal classification through a bidirectional approach	19
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease	19
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply	19
Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States	19
Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018	18
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post‐inflammatory polyps	18
Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland	18
Effect of time to pre‐emptive transjugular intrahepatic portosystemic shunt on patient outcome, a UK multicentre cohort study	18
Systematic Review: Ultrasound Goes Echo—Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound	18
Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply	18
Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply	18
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality	18
Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy	18
	18
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study	18
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission	18
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites	18
Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?	18
Type 1 diabetes and microscopic colitis: A nationwide matched case–control study in Sweden	18
Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply	18
Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma	18
Age at treatment initiation predicts response in children with chronic hepatitis B	18
Editorial: Cholestasis Is an Important Marker for Evaluating Clinical Outcomes and Prognosis in Severe Burns and Critically Ill Patients	18
Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma—Authors' reply	17
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply	17
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management	17
Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study	17
Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions	17
Issue Information	17
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply	17
Editorial: colorectal cancer in elderly‐onset inflammatory bowel disease—what is the risk?	17
Natural history and impact of irritable bowel syndrome‐type symptoms in inflammatory bowel disease during 6 years of longitudinal follow‐up	17
	17
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and <	17
Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment	17
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply	17
Editorial: immunosuppression and SARS‐CoV‐2 vaccination—where do we stand?	17
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	17
Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent	17
Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply	17
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease—a Danish cohort study	16
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!	16
Editorial: the burden of alcohol‐related liver disease emergency admissions in England may be twice as high as previously thought—authorsʼ reply	16
Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply	16
Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era?	16
Letter: 5‐aminosalicylate maintenance treatment in mild Crohn's disease	16
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet?	16
Editorial: Faecal microbiota transplantation inIBS—Moving closer or away from success? Authors' reply	16
Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’	16
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ reply	16
Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply	16
Altered serum bile acid composition is associated with cardiac dysfunction in cirrhosis	16
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism. Authors' reply	16
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain	16
Letter: Low to moderate alcohol intake and progression of non‐alcoholic fatty liver disease	16
Editorial: the other bug	16
Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply	16
Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort	16
Superficial oesophageal mucosal innervation may contribute to severity of symptoms in oesophageal motility disorders	15
Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF	15
Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease	15
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease	15
Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study	15